---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-018371"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:16:34.813959+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protara Q4 net loss $39.0M; cash $102.3M; TARA-002 data expected Q2 2023

## Summary
- Net loss Q4 2022: $39.0M ($3.46 per share) vs $10.2M ($0.91) in Q4 2021; includes $29.5M goodwill impairment.
- Full year 2022 net loss $66.0M ($5.86 per share) vs $47.3M ($4.21) in 2021; R&D expense $16.8M, G&A $20.7M.
- Cash, equivalents, and marketable debt securities $102.3M as of Dec 31, 2022; expected to fund operations into 2025.
- Phase 1a data from ADVANCED-1 trial of TARA-002 in NMIBC expected in Q2 2023; Phase 2 trial in LMs to start 2H 2023.
- Prospective study of IV Choline Chloride in IFALD ongoing; results expected Q3 2023.

## SEC filing metadata
- accession: 0001213900-23-018371
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390023018371/0001213900-23-018371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390023018371/ea174762-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-018371
- JSON: https://secwatch.observer/filing/0001213900-23-018371.json
- Plain text: https://secwatch.observer/filing/0001213900-23-018371.txt

## Key facts
- Earnings Releases
  Protara Therapeutics, Inc. reported the quarter and year ended December 31, 2022 results: net income net loss of $39.0 million, or $3.46 per share.
  - Period: the quarter and year ended December 31, 2022
  - Net income: net loss of $39.0 million, or $3.46 per share
  - Result: reported results
  source text: On March 8, 2023, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390023018371/0001213900-23-018371-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.